Match!
Andrea Ardizzoni
University of Bologna
507Publications
48H-index
10.1kCitations
Publications 507
Newest
#1Marika Cinausero (University of Udine)H-Index: 7
#2Karim Rihawi (UNIBO: University of Bologna)H-Index: 8
Last.Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
view all 6 authors...
Abstract Malignant pleural mesothelioma (MPM) is a rare cancer of the pleural surfaces frequently related to asbestos exposure. It is characterized by a poor prognosis even for patients treated with trimodality therapy, including surgery, chemotherapy and radiotherapy. Moreover, the majority of patients are not candidates for surgery due to disease advanced stage or medical comorbidities. For these patients, the survival rate is even lower and few therapeutic options are currently available. Nev...
Abstract In few years several hormonal agents have been tested in patients with non-metastatic castration resistant prostate cancer (nmCRPC) leading to an impressive improvement in terms of metastases free survival. We performed a meta-analysis aimed to: 1) estimate the pooled impact of new hormonal compounds in terms of metastases free survival, overall survival in overall and specific subpopulations and 2) Estimate the impact of high-grade toxicities of these drugs. 881 studies exanimated betw...
#1Ken Nakagawa (Kindai University)H-Index: 70
#2Edward B Garon (UCLA: University of California, Los Angeles)H-Index: 1
Last.Shaker R. DakhilH-Index: 52
view all 116 authors...
Summary Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC. Methods This is a worldwide, double-blind, phase 3 trial done in 100 hospitals, c...
#1Maria A. Pantaleo (UNIBO: University of Bologna)H-Index: 26
#2Giuseppe Tarantino (UNIBO: University of Bologna)H-Index: 5
Last.Annalisa Astolfi (UNIBO: University of Bologna)H-Index: 31
view all 19 authors...
ABSTRACTFew studies were conducted investigating the immunological profiles in gastrointestinal stromal tumors (GIST). Adaptive and innate immune cells are present in the tumor microenvironment, in...
Abstract Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with checkpoint inhibitors revolutionized treatment in many cancer types and results from the IMpower133 study, a double-blind placebo-controlled phase III trial, showed overall survival benefit for atezolizumab when added to standard platinum-etoposide chemotherapy in first-line SCLC setting for the first time since ye...
#1Elisa Capizzi (UNIBO: University of Bologna)H-Index: 10
#2Filippo Gustavo Dall’Olio (UNIBO: University of Bologna)H-Index: 3
Last.Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
view all 8 authors...
Abstract Objectives Patients harboring rearrangements of the ROS1 gene are eligible for first-line therapy with Crizotinib, which represents the best available treatment option. Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK by analogy and include tumors with 5' deletions. However, the probability of response to Crizotinib in patients with 5' deletion in ROS1 is unknown given the rarity of this condition. Materials and methods We hereby descr...
#1Emanuel Raschi (UNIBO: University of Bologna)H-Index: 22
#2Ippazio Cosimo Antonazzo (UNIBO: University of Bologna)H-Index: 4
Last.Fabrizio De Ponti (UNIBO: University of Bologna)H-Index: 37
view all 6 authors...
12345678910